(Reuters) - Two drugs being developed by GlaxoSmithKline Plc - each designed to block different pathways used by cancer cells - have been shown in a small clinical trial to curb Melanoma with fewer side effects than current therapies. The experimental drugs are dabrafenib, designed to work in patients with a mutation of a gene known as BRAF, and trametinib, which interferes with a protein known as MEK. The drug combination was tested in patients with advanced melanoma and a mutation in the BRAF gene. About half of all melanomas - the deadliest form of Skin Cancer - have the genetic aberration. ... read more..